Vimovo is a combination of naproxen (an NSAID) and immediate-release esomeprazole (a proton-pump inhibitor, or PPI). The immediate release formulation allows for sequential release of the active components -- esomeprazole is delivered first, then naproxen is released. Vimovo was approved by the FDA on April 30, 2010 for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and to decrease the risk of gastric ulcers in patients who have a higher risk of developing NSAID-associated gastric ulcers.
Learn more about Vimovo -- when it is prescribed, warnings, precautions, common side effects, and signs of overdose in Vimovo - What You Need to Know.
Related Resources:
- All About Vimovo
- Nexium Reduces Risk of Ulcers For Long-term NSAID Users
- GI Bleeding - Don't Ignore Symptoms
- Arthritis Drugs - What Are My Options?
Sign Up: Free Arthritis Newsletter
Photo by tdenham (stock.xchng)
